Joslin Diabetes Center is a leader in continuing education for healthcare professionals. Joslin's CME and CE activities promote the highest standards of care, drawing on up-to-date medical literature as well as cutting-edge research conducted at Joslin to provide current, relevant, and evidence-based findings from Joslin faculty and other experts. Our mission is to help providers offer their patients optimal management of diabetes and its related conditions, improved health outcomes, and enhanced quality of life.
Proven Success with Educational Outcomes
Joslin Diabetes Center has been at the forefront of measuring educational outcomes for our activities, based on the levels defined by Moore et al.1 We have been involved in several specific projects that measure the impact of our educational activities on clinician performance measures (Level 5) and patient outcomes measures (Level 6). Please click here to read about one of these initiatives entitled Targeting Type 2 Diabetes: Achieving Glycemic and Cardiometabolic Goals. This initiative was supported by educational grants from GlaxoSmithKline LLC and Merck Sharpe and Dohme Corp.
1 Moore DE Jr, Green JS, Gallis HA. Achieving desired results and improved outcomes: integrating planning and assessment throughout learning activities. J Contin Educ Health Prof. 2009;29(1):1-15.
Current Enduring Activities
Data supporting the use of GLP-1 receptor agonists in combination with basal insulin demonstrates the value of this treatment approach. This activity will provide learners with an update on data supporting combination therapy. It will empower diabetes specialty clinicians to more effectively identify people for whom this combination therapy would be indicated based on an assessment of their pathophysiology. Finally, it will highlight strategies to overcome barriers to injection therapy, and facilitate coordinated care with primary care providers.
This activity is supported by an educational grant from sanofi-aventis U.S. and is offered through our partner myCME. Expiration date: March 11, 2017.
Many clinicians delay initiation of needle-delivered medications as long as possible in T2DM, allowing patients to use lifestyle modifications plus metformin and eventually additional oral medications for an extended time, even when outcomes remain suboptimal. Not all patients benefit from this conservative approach, however. In the case presented here, the combination of an elevated A1C and a patient’s commitment to do whatever it takes to manage his diabetes demonstrate the value of expediting advancement to non-oral antidiabetes medications.
This activity is supported by an educational grant from Lilly USA, LLC and is offered through our partner myCME. Expiration date: June 16, 2016.
Biosimilar Insulins and Their Implications for Clinical Practice
Biosimilar medications are “highly similar” to an already FDA-approved biological product. One biosimilar is approved in the US, with more sure to follow in the near future, including a biosimilar insulin that is likely to have a significant impact on diabetes management. Although they will be responsible for ensuring safe and effective use of biosimilars, many clinicians are not familiar with the distinctions between biosimilars and generic drugs, including the different approval processes and regulatory issues surrounding these agents. These webcasts present the perspective of an endocrinologist versed in regulatory approval processes, and endocrinologist with expertise in insulin management, and a clinical pharmacist.
These activities are supported by an educational grant from Lilly USA, LLC and are offered through our partner myCME.
Link to Roundtable webcast. Expiration date: May 5, 2016.
Link to Q&A webcast. Expiration date: July 10, 2016.
SGLT2 Inhibitors in Type 2 Diabetes: Incorporating New Approaches Into Practice Through an Interdisciplinary Exploration
Type 2 diabetes mellitus (T2DM) remains undertreated in many patients, partly due to the progressive nature of the disease and the limitations of traditional therapies. Despite the plethora of available therapeutic options, adequate glycemic control is still often difficult to achieve, leading to serious complications. In this multidisciplinary Roundtable discussion, 4 key experts will provide their unique perspectives about SGLT2 inhibitors and their role in T2DM treatment. Two case studies allow the learner to apply knowledge to simulated patients.
These activities are supported by an educational grant from AstraZeneca LP and are offered through our partner myCME
Link to Roundtable webcast. Expiration date: June 29, 2016.
Link to Case 1: A Patient With Hypertension and Poorly Controlled Type 2 Diabetes. Expiration date: June 29, 2016.
Link to Case 2: A Complex Patient With Type 2 Diabetes and Moderate CKD. Expiration date: June 29, 2016.
Joslin at World Congress for CPD 2016
Joslin recently presented a session and a poster based on the performance improvement grant entitled Comparison of Methods for Assessing Clinical Performance Improvement in Primary Care.View the poster here
Joslin Clinical Guidelines
To assist physicians and other healthcare professionals in managing the care of their patients with diabetes, Joslin offers approved clinical guidelines on a variety of topics including Adult Diabetes, Pharmacological Management of Type 2 Diabetes, and Continuous Glucose Monitors.